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During a measles vaccine trial in a rural area 
of Senegal, antibody status was examined within 
10 days of exposure for 228 previously vaccinated 
and 313 unvaccinated children more than 12 
months old who were exposed to measles at 
home. Thirty-six percent of the children devel- 
oped clinical measles, the clinical diagnosis be- 
ing confirmed for 135 of the 137 children from 
whom 2 blood samples were collected. Vaccine 
efficacy was 90% (95% confidence interval, 83 to 
94%). The hemagglutinin-inhibiting antibodies 
(HI) or plaque neutralizing antibodies (PN) as- 
says were equally efficient in predicting suscep- 
tibility and protection against measles. Vacci- 
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nated children who had no detectable HI or PN 
antibodies at exposure had significant protec- 
tion against measles compared with seronega- 
tive unvaccinated children (HI vaccine efficacy, 
49% (95% confidence interval, 21 to 68%); PN 
vaccine efficacy, 43% (95% confidence interval, 12 
to 62%)). The attack rate was high for children 
with a titer of 40 to 125 mIU) 67% (4 of 6) of those 
with a positive hemagglutinin-inhibiting anti- 
body test and 36% (13 of 36) of those with a 
positive PN test developed measles. Attack rates 
among children with HI or PN titers above 125 
mIU were 2% (6 of 295) and 3% (7 of 258), respec- 
tively. Because titers of 5120 mIU have been 
found to offer little protection in another study, 
this antibody level may be the best screening 
value for assessing susceptibility and protection 
against measles. However, it should be noted that 
many seronegative vaccinated children are pro- 
tected against measles infection. 
INTRODUCTION 
The presence or absence of measles antibodies has 
been assumed to correlate with protection and suscep- 
tibility to  natural measles infection.’ Measles immuni- 
zation policies for developing countries have been 
based largely on immunogenicity studies.2’ Given the 
age-specific incidence pattern observed in a rural area 
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of Kenya and applying the assumptions that serocon- 
version is equivalent to  protection and nonseroconver- 
sion is equivalent to  full susceptibility, the number of 
measles cases prevented by vaccination at different 
ages was projected in order to reach the conclusion that 
9 months represented the optimal age for measles 
immunization.2 However, there are now a number of 
reports4-’ of individuals who had measles antibodies 
after immunization and later developed measles infec- 
tion. A study from the United States of 80 blood donors, 
of whom 8 developed measles during an outbreak in a 
university college, reported that individuals with low 
measles antibody titers (1120 mIU) were susceptible 
to infection4 On the other hand although virtually 
everybody contracts measles in virgin soil popula- 
t i o n ~ , ~  observations from immunized populations”’ l1 
suggest that undetectable antibodies may not neces- 
sarily imply that the individual is fully susceptible to 
disease. Presumably they have low undetectable anti- 
bodies andor cellular immunity. 
During a trial of high titer measles vaccine in rural 
Senegal,‘ we collected blood samples shortly after ex- 
posure from children living in the same compound as a 
measles case. Thus it was possible to assess suscepti- 
bility among vaccinated children with no antibodies to  
measles, as well as protection among children who had 
antibodies by either hemagglutinin-inhibiting (HI) or 
plaque neutralization (PN) assays. 
SUBJECTS AND METHODS 
Study population, health conditions and demo- 
graphic surveillance. The study was conducted in 
Niakhar, Senegal, a rural area with around 25 000 
inhabitants mostly belonging to  the Sereer ethnic 
group and living in large compounds in scattered 
hamlets.12-14 Within a compound there may be several 
households with each having a common cooking pot. 
Within a household people may sleep in different huts. 
Infant and childhood mortality in the study area was 
112/1000 and 253/1000, respectively, in the period 1984 
to 199014 and the principal causes of postneonatal 
mortality were diarrhea, malaria, respiratory infec- 
tions, measles and malnutrition. In a survey conducted 
in 1990, 3% (33 of 1007) of children ages 2 to 4 years 
had weight for height of less than 2 z scores and 36% 
(368 of 1010) were stunted with height for age of less 
than 2 z scores. The study area has two public dispen- 
saries and one private Catholic dispensary. 
From 1987 the demographic surveillance system has 
been based on weekly visits by 12 field assistants to  all 
the 1700 to 1800 compounds in the study area, in order 
to  obtain information on births, migrations, marriages, 
deaths and infections (measles and whooping cough). 
Measles surveillance and blood sampling. A 
trial of high titer measles vaccine was initiated in July, 
1987.6 In connection with the trial of high titer vaccine, 
’ 
surveillance for acute cases of measles was initiated in 
the area. The present analysis includes children who 
were exposed to  or developed measles between July, 
1987, and December, 1990. Vaccine efficacy has previ- 
ously been analyzed for the subgroup of children who 
participated in the trial of high titer measles vaccine.6 
When a field assistant was informed about a case of 
suspected measles, the project physician was called to 
examine the child. During the visit information was 
sought on how the first case had contracted measles 
and contacts were traced. Hence new measles cases 
were found both by routine surveillance and through 
active follow-up of contacts by the physician. In order 
to  assess the completeness of the surveillance, mothers 
were asked in the census whether their children had 
had measles. Fewer than 5% additional cases were 
found this way, and virtually all of these cases had 
occurred outside the study area. 
At the first visit in a compound a census was made of 
all children less than 15 years of age. When parents 
consented a blood sample was taken by finger prick 
from cases and exposed children who had no previous 
history of measles infection. Convalescent samples 
from children who developed measles were collected 
4 to 5 weeks after the beginning of symptoms but 
not from exposed children with no signs of measles 
infection. 
Clinical examination and case definition. Com- 
pounds with suspected measles cases were visited at 
least twice a week for the first 4 weeks in order to 
observe the development of symptoms, to  detect new 
cases as early as possible and to provide treatment. 
During each visit the presence and severity of the 
following symptoms were recorded: Koplik spots; rash; 
desquamation; conjunctivitis; stomatitis; cough; respi- 
ratory symptoms; diarrhea; and temperature. At the 
end of each examination the clinician evaluated 
whether the case was probable, possible or not measles. 
With further follow-up possible cases were reclassified 
as either “probable” or “not measles.” All children with 
a clinical diagnosis of probable measles had a typical 
rash andor a typical desquamation. 
Classification of cases and intensity of expo- 
sure. A child who developed measles more than 6 days 
after the first case (index case) in the same compound 
was classified as a secondary Cases with an 
interval of less than 6 days were considered co-index 
cases. In the present study cases belonging to the first 
generation developed measles within an interval of 8 to  
19 days after exposure. Secondary cases and exposed 
children were classified according to  the intensity of 
contact with a measles case, in the same hut, same 
household or only same compound.15 If there were two 
possible sources of infection, the closer contact was 
considered the more likely. A child may have been 
. 
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exposed in the first generation without contracting 
measles, only to become infected in a later generation 
after a sibling had developed measles in the same 
hut.15 In the present analysis we used only the closest 
exposure for each child. 
Measles vaccination in the study area and im- 
munization status. There were measles vaccination 
campaigns from 1979 to 1983 in Niakhar and again in 
1986 to 1987 during the accelerated phase of the 
Expanded Programme on Immunization. However, un- 
til 1987 coverage was 10w.15 From July, 1987, Bacillus 
Calmette-Guérin, diphtheria, pertussis, tetanus, polio, 
measles and yellow fever vaccines were offered system- 
atically in immunization sessions organized once a 
month at each of the three health centers as part of 
trials of measles and pertussis vaccines.6, 16, l7 The 
coverage among 1- to 2-year-old children born in the 
study area increased from 36% in 1986 to 82% in 1990. 
From 1983 to 1986 information on vaccines were 
gathered through the annual censuses and health 
centre immunization registers. Documentation pro- 
vided during the previous campaign may have been 
incomplete or lost subsequently. Hence some individu- 
als were probably immunized without this being re- 
corded by the project. For the children born after 
February, 1987, the project provided nearly all measles 
immunizations and the quality of the information on 
immunization status is likely to be much better than 
for the children born earlier.6 The analysis was there- 
fore adjusted for the period in which the children were 
born. Children who had measles within 2 weeks of 
vaccination were classified as unvaccinated. 
Analysis of blood samples and seroconversion. 
Blood samples were analysed for measles HI antibodies 
at the MRC Laboratories, The Gambia." The sensitiv- 
ity of this test was 31.25 mIU. Because the test started 
with a 1:2 dilution, the minimum detectable titer was 
62.5 mIU. Neutralization antibodies were measured by 
a standard plaque reduction neutralization assay 
(PN1.l' This assay, which used an inoculum of 30 to 50 
plaque-forming units of low passage Edmonston mea- 
sles virus (courtesy of Dr. P. Albrecht), had a sensitiv- 
ity of 4 mIU. With a starting serum dilution of l : l O ,  the 
minimum detectable titer of antibody was 40 mIU/ml. 
Three percent of the samples (24 of 758) with grossly 
discrepant values between the 2 assays were retested 
in both tests, in case samples had been misread or 
misnumbered, and the results of the second test were 
regarded as valid. 
Protection in relation to antibody titer has been 
analyzed for children from whom a blood sample was 
collected within 10 days of the onset of symptoms in the 
index case in the Seroconversion was ana- 
lyzed for children from whom the first sample was 
collected immediately before infection or within 3 days 
of the onset of symptoms, with the second sample 
obtained 17 to 57 days after the onset of disease. A 
4-fold increase in titer in conjunction with clinical 
features of measles was considered proof of acute 
infection. 
Statistics. The protective efficacy against measles 
infection was examined by comparing secondary attack 
rates (SAR)  for vaccinated and unvaccinated children 
Vaccine efficacy (%) = 
(1 - (SAR for vaccinatedSAR for unvaccinated)) x 100 
Relative risks and Greenland-Robins approximate 95% 
confidence intervals have been calculated using the 
EPIINFO program. 
RESULTS 
Study population and seropositivity. Among the 
1218 resident children younger than 15 years of age 
exposed to measles in the compound, 215 had had 
measles. Of the 1013 children with no history of previ- 
ous measles infection, 255 (25%) were absent os refused 
and 758 (75%) had a blood test taken, 588 (78%) within 
10 days and 170 (22%) more than 10 after exposure. 
Among the 588 children who provided a blood sample 
within 10 days, 245 (42%) of the children were vacci- 
nated and 343 (58%) were unvaccinated. There was no 
difference in the level of HI antibodies among those 
examined within the first 10 or even within the first 20 
days of exposure (data available at request). In order to  
avoid confounding by maternal antibodies, the main 
analysis was confined to  the 541 (92%) of the 588 
children who were more than 1 year old (>365 days) 
when the first blood sample was taken. 
Among immunized children 88% had detectable HI 
antibodies to measles (Table 1). The proportion of 
seropositive children decreased with time since immu- 
nization (P = 0.001) (data available at request). Of 313 
unvaccinated children with no history of measles-like 
rashes 32% had detectable HI antibodies to measles. 
The seropositive unimmunized children (Table 1) were 
significantly older than the seronegative unimmunized 
(P < 0.001, Kruskal-Wallis, chi square = 20.8) and the 
immunized children (P < 0.001, Kruskal-Wallis, chi 
square = 104.2). 
Serologic responses in relation to clinical mea- 
sles. One hundred ninety-five children developed clin- 
ical measles; the first sample was taken from them on 
an average of 8 days before the onset of symptoms 
(range, 35 days before symptoms to the first day of 
symptoms). For 137 children a second blood sample 
was taken more than 2 weeks after onset of symptoms 
(range, 17 to 57 days); 135 children (99%) had a 4-fold 
or greater increase in titer. One child had no detectable 
antibody in either sample, and in one child the initial 
titer fell from 8000 mIU to 2000 mIU. Thus the 
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TABLE 1. Secondary attack rates according to  immunization status, HI seropositivity test and intensity of exposure: 
Niakhar, 1987 to  1990 
Note: When the data were analyzed in relation to  PN antibodies, the attack rates were 48% (11 of 23) for seronegative 
vaccinated, 1% (2 of 192) for seropositive vaccinated, 82% (149 of 181) for seronegative unvaccinated and a higher rate of 18% 
(18 of 102) for nonvaccinated seropositive children. 
Vol. 14, No. 3, March, 1995 
Secondary Attack Rate (%) 
Type of Exposure Vaccinated against measles Nonvaccinated 
Seronegative Seropositive Seronegative Seropositive 
~~ 
Median age (months) 39 46 86 115 
Compound 29 (2/7)* O (0/51) 64 (30/47) 6 (U171 
Hut 33 (5/15) 1 (mos) 88 (95/108) 4 (2/56) 
Household 80 (U51 2 (U421 84 (49/58) 19 (5/27) 
Total 41 (1U27) 1 (2/201) 82 (17U213) 8 (8/100) 
a Numbers in parentheses, number of caseshumber exposed. 
predictive value of a clinical diagnosis was 99% accord- 
ing to  the criteria set for this study. 
Vaccine efficacy. The secondary attack rate (Table 
1) was higher if exposure occurred in the household 
(relative risk, 1.49 (95% confidence interval, 1.15 to 
1.92)) or in the same hut (relative risk, 1.35 (95% 
confidence interval, 1.08 to  1.69)) than from someone 
living in the compound but in a different household, 
whereas there was no difference between the attack 
rates in the household or hut. There was no difference 
in attack rate by age or sex. Hence we have adjusted for 
intensity of exposure in the analysis of vaccine efficacy. 
Analyzed without regard to the serologic status, vac- 
cine efficacy was 90% (95% confidence interval, 83 to  
94%) for vaccinated children when compared with 
children with no history of measles infection or of 
measles immunization. 
Secondary attack rates among seronegative 
and seropositive children. If the analysis of attack 
rates is limited to  all HI-seronegative children (Table 
l), the vaccinated seronegative children had a protec- 
tive efficacy of 49% (95% confidence interval, 21 to 
68%) compared with seronegative unvaccinated chil- 
dren. The tendency remained the same (vaccine effi- 
cacy, 50% (95% confidence interval, 8 to 73%)) if the 
analysis was limited to  the children who had not been 
enrolled in the high titer trial.3 The protective efficacy 
among vaccinated children who were seronegative in 
the PN antibody assay was 43% (95% confidence inter- 
val, 12 to  62%) (data available on request). Seroposi- 
tivity and attack rates were essentially similar when 
the analysis was limited to samples collected within 3 
days of exposure (Table 2). 
Among the HI-seronegative vaccinated children (Ta- 
ble l), six had received a high titer measles vaccine at 
5 months and had been tested at 10 months of age. 
Three children who developed measles had titers of 63, 
63 and 500 mIU at 10 months of age. The three 
seronegative children who did not develop measles had 
titers of <63, 125 and 250 mIU at 10 months of age. 
Vaccinated children who were seropositive in either 
the HI (Table 1) or PN test had significantly lower 
attack rates than the seropositive unvaccinated chil- 
dren. Twenty-three children who had a positive blood 
sample at exposure developed measles: in 7 both HI 
and PN antibodies were detected; in 3 only HI antibod- 
ies were detected; and 13 were positive only in the PN 
assay. The first clinical symptoms occurred from 0 to  28 
days after the sample had been collected (data avail- 
able at request). 
Protective HI or PN antibodies. All samples from 
children exposed within 10 days were assayed by the 
more sensitive PN test. After logarithmic transforma- 
tion PN and HI results were strongly correlated (T = 
0.85 (95% confidence interval, 0.83 to  0.88)). In Table 3 
we present the attack rate among immunized and 
nonimmunized children according to the antibody titer 
measured by the two tests. The attack rates were high 
for children with titers below 125 mIU in either test. 
Among children with higher antibody titers, 2 to 3% 
TABLE 2. Secondary attack rates according to  immunization status, seropositivity in the plaque neutralization test and 
intensity of exposure (only children exposed within 3 days of the first case in the compound): Niakhar, 1987 to  1990 
Secondary Attack Rate (%) 
Type of Exposure Vaccinated against measles Nonvaccinated 
Seronegative Seropositive Seronegative Seropositive 
Compound O (0/13) 70 (7/10) O (0/3) 
Household 100 (2/2)* o (0/10) 90 (9/10) 27 (3/11) 
Total 40 (2/5) 2 (U46) 86 (32/37) 21 (5/24) 
Hut O (0/3) 4 (U231 94 (16/17) 20 (2/10) 
* Numbers in parentheses, number of caseshumber exposed. 
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TABLE 3. Attack rates among children exposed in  the 
compound according to HI and PN antibody titers (mIU) 
within 10 days of exposure: Niakhar, 1987 to 1990 
Attack Rate 
HI Titer (mrU) % PNTiter(mrU1 % 
Unimmunized children 
4 3  
63-125 
250-1000 
>loo0 
Total 
<63 
Immunized children 
63-125 
250-1000 
>loo0 
Total 
All children 
<63 
63-125 
250-1000 
>loo0 
Total 
82 (174/213)* 
100 (4/4) 
O (0/33) 
6 (4/63) 
58 (182/313) 
41 (1U27) 
o (0/2) 
2 (U631 
1 (U136) 
6 (13/228) 
77 (185/240) 
67 (4/6) 
1 (U96) 
3 (5/199) 
36 (195/541) 
<40 
40-125 
126-249 
250-1000 
>loo0 
<40 
40-125 
126-249 
250-1000 
>loo0 
<40 
40-125 
126-249 
250-1000 
>loo0 
82 (149/181) 
57 (13/23) 
11 (1/9) 
5 (2/44) 
8 (2/26) 
59 (167/283) 
48 (11/23) 
O (0/13) 
5 (U211 
1 (U991 
O (0/59) 
6 (13/215) 
75 (160/204) 
36 (13/36) 
7 (2/30) 
2 (3/143) 
2 (2/85) 
36 (180/498) 
* Numbers in parentheses, number of cases/number exposed. 
developed measles, and there was no difference in the 
pattern of protection depicted by the two antibody tests. 
Screening values for susceptibility and protec- 
tion. Because the attack rates were.highest among the 
unvaccinated children exposed in the household or hut, 
we limited the analysis of the best screening value to 
the children exposed within the household or hut and 
who had been examined in both tests (Table 4). The two 
antibody assays gave very similar results. In both 
assays raising the screening value to 125 mIU im- 
proved the sensitivity for predicting susceptibility 
without seriously jeopardizing the prediction of protec- 
tion. The best combination of sensitivity and specificity 
was obtained by using an HI antibody value of 5125 
mIU as the indicator of susceptibility. Results were the 
TABLE 4. Sensitivity and specificity of various antibody 
titers for susceptibility to  clinical measles among exposed 
persons 
HI antibody titer 
of 4 3  mIU 
Sensitivity 82 (9/11)* 95 (127/134) 
Specificity 93 (137/148) 77 (64/83) 
HI antibody titer 
of 5125 mIU 
Sensitivity 82 (9/11) 98 (131/134) 
Specificity 92 (136/148) 77 (64/83) 
PN antibody titer 
of <40.mIU 
Sensitivity 82 (9/11) 88 (118/134) 
Specificity 94 (139/148) 83 (69/83) 
PN antibody titer 
of 5125 mIU 
Sensitivity 82 (9/11) 97 (130/134) 
Specificity 89 (132/148) 75 (62/83) 
* Numbers in parentheses, number of cases/nnmber exposed. 
94 (136/145) 
87 (20U231) 
97 (140/145) 
87 (200/231) 
88 (127/145) 
90 (208/231) 
96 (139/145) 
84 (194/231) 
same if we did not remove the discrepant values and 
use the first antibody results; for example sensitivity 
and specificity of an HI antibody value of 5125 mIU 
were 97% (139 of 144) and 87% (200 of 231), respec- 
tively. 
DISCUSSION 
Measles is currently estimated to kill 1.4 million 
childredyear in developing countries. Many of these 
deaths occur in children who develop measles before 
the current age at immuni~ation.~ Hence changes in 
vaccine strategy or type of vaccine which permit a 
reduction in the age of immunization are desirable, 
because they may contribute to the reduction of mea- 
sles-associated mortality. The World Health Organiza- 
tion recommendations regarding type and age at mea- 
sles immunization have been based mainly on 
seroconversion studies.2’ There is some indication 
that antibody titers fall to  low or undetectable levels in 
populations with little reexposure. This problem may 
be larger in areas where immunization was introduced 
early and the initial antibody response was lower. 
Hence it seems possible that with increasing coverage 
in many developing countries, it may be necessary to 
introduce reimmunization in order to prevent out- 
breaks among older children. It is therefore of interest 
to know how well antibody titers correlate with protec- 
tion. 
We did not have preexposure samples but analyzed 
samples from children who had been examined within 
10 days of exposure to  measles (Table 1). Even if the 
samples were restricted to those collected within 3 days 
of exposure, the attack rates according to  serologic and 
immunization status remained the same (Table 2). 
Furthermore because there was no indication of 
booster responses among children examined within the 
first 10 days after exposure, it seems likely that the 
antibody titers measured in this study represent pre- 
exposure levels. 
We have previously analyzed antibodies for the sub- 
set of children included in a trial of high titer Edmon- 
ston-Zagreb and Schwarz measles vaccines6; vacci- 
nated children who were HI-seronegative had some 
protection compared with seronegative unvaccinated 
children. This finding was confirmed in the present 
larger study including children who had not been 
enrolled in the high titer trial and had not received 
high titer vaccine. Because seronegative children pro- 
tected against measles could have had low titers of 
neutralization antibodies undetectable by the HI as- 
say, we analyzed all samples from children who were 
exposed within 10 days by the plaque neutralization 
test. However, analysis of antibody titers using the PN 
assay did not alter the conclusion that seronegative 
vaccinated children had some protection against mea- 
sles. Presumably some children had an anamnestic 
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antibody response or sufficient cellular immunity to 
provide protection against clinical infection even 
though they had undetectable antibodies. Some sero- 
negative unvaccinated children exposed in the hut or in 
the household did not develop clinical measles, but 
because these children were not bled a second time, it 
was not possible to  ascertain whether they had subclin- 
ical infection. From the present study up to  50% of 
immunized children who are seronegative may have 
sufficient immunity to prevent clinical disease and this 
estimate is not changed by using a more sensitive 
assay. 
Measles antigen is presented to  both T and B cells in 
the normal child, and a strong correlation between the 
presence of antibodies and cell-mediated immunity 
makes the separate contribution of each difficult to 
determine. However, children with congenital agam- 
maglobulinemia contract measles and pursue a typical 
clinical course with rash and subsequent immunity 
despite the absence of detectable measles antibodies 
postinfection2' and it has been suggested that antibody 
production in measles is of minimal or no importance.'l 
On the other hand immunoglobulin prevents infection 
in susceptible contacts when given within a few days of 
exposure, and humoral immunity may therefore play 
an important role in the prevention of systemic infec- 
tion. Hence protection can be provided by both humoral 
and cellular immunity. Thus lack of antibodies may not 
indicate susceptibility to disease as demonstrated by 
our observations and observations in agammaglobu- 
linemic children. 
The presence of measles antibody is usually believed 
to protect against acquisition of disease.'> However, 
there have been some reports from developing coun- 
tries of children with antibodies developing me as le^,^, 
and the degree of protection may depend on the amount 
of antibody and the intensity of exposure. For example 
in virgin soil epidemics, protective doses of immuno- 
globulin have been found not to  protect but only to 
modify measles infe~tion.~ One study of blood donors 
from the United States indicated that 8 of 9 individuals 
with PN-positive titers 1120 mIU developed clinical 
disease when exposed to measles whereas several do- 
nors with higher titers had significant increases in 
titers but did not develop the full clinical picture, 
although some reported symptoms." Our data from 
Senegal indicated that children with antibody titers 
5125 mIU in either the HI or PN test had only limited 
protection against measles, whereàs children with ti- 
ters above 125 mIU in either test had low attack rates 
(Table 3). Hence a level of 125 mIU of measles antibod- 
ies may be the best screening value for determining 
likely protection against measles. It should be noted 
that some children with higher titers developed clinical 
measles. Although the PN test was able to distinguish 
somewhat lower amounts of antibody than the HI test 
and neutralizing antibodies are believed to be more 
relevant to  protection, the PN test did not provide a 
better assessment of protection and susceptibility than 
the HI test. 
A surprising and unexplained observation was that 
most of the children who had antibodies but developed 
measles were found in the unvaccinated group and not 
in the immunized group. The seropositive "unimmu- 
nized" children were considerably older than other 
groups (Table 1) and they may have had antibodies 
because of undocumented measles immunizations ei- 
ther outside the area or  in the previous less well- 
documented campaigns or to previous measles infec- 
tion. The lower antibody titers and higher attack rates 
in this group may be related to a longer time since the 
suspected immunization. It is also possible that some of 
the children in this group had experienced unrecog- 
nized measles infection. 
Our study as well as those of others" suggest that the 
assumptions of a clear correlation between seropositiv- 
ity and protection or seronegativity and susceptibility 
are not inviolate. Even if standard assays are substi- 
tuted with the more sensitive PN assay, the absence of 
detectable antibody is not equivalent to  susceptibility; 
also some of the immunized children with antibodies 
may develop measles. Raising the cutoff to  an antibody 
titer of 125 mIU would improve the prediction of 
susceptibility. Because there were similar findings in 
an American study," titers 5125 mIU should not be 
considered protective in studies of vaccine-related an- 
tibody responses or in monitoring antibody titers in 
different populations. 
Serologic data provide some guidance to the protec- 
tive efficacy of various immunization strategies. How- 
ever, vaccination policies affecting millions of children 
should not be based exclusively on projections from 
serologic studies but on specific studies comparing the 
impaci of alternative policies on morbidity and mortal- 
itY.17, 22 
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